Announcement • Jun 28
Redsense Medical AB Launches Digital Training Platform for Healthcare Professionals, Providers and Distributors Redsense Medical AB announced the launch of a new digital training platform for healthcare professionals, healthcare providers and distributors. The platform brings Redsense training materials, product information, quick guides, tutorials, contact details and other educational resources into one central location. The purpose is to make training and retraining more accessible and to support consistent use of Redsense products across markets. Easier access to training helps healthcare professionals stay confident in the daily use of Redsense products, supporting safer dialysis care for the patients who rely on them. In the United States, Redsense is coordinating access together with the education and training departments of several of its largest healthcare provider customers. Outside the United States, healthcare professionals and distributors will be able to request access through Redsense's website or through local distribution partners. Board Change • Jun 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Non-Independent Chairman Susanne Olauson is the most experienced director on the board, commencing their role in 2013. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • May 22
Redsense Medical AB (publ) Appoints Michael Kraus as Director Redsense Medical AB (publ) at its Annual General Meeting held on May 20, 2026 approved to elect Michael Kraus as Directors for the period until the end of the next AGM. Reported Earnings • May 21
First quarter 2026 earnings released First quarter 2026 results: Revenue: kr7.20m (up 48% from 1Q 2025). Net income: kr1.12m (up kr4.27m from 1Q 2025). Profit margin: 16% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Announcement • Apr 21
Redsense Medical AB (publ) to Report Q1, 2026 Results on May 20, 2026 Redsense Medical AB (publ) announced that they will report Q1, 2026 results on May 20, 2026 Announcement • Jan 21
Redsense Medical AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026 Redsense Medical AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026 Announcement • Nov 09
Redsense Medical AB (publ) Initiates Sales Activities in Australia Following TGA Approval of Redsense Clamp Redsense Medical AB (publ) announced that the Cincinnati Clamp System has been granted regulatory approval from the Australian Therapeutic Goods Administration (TGA), allowing the product to be sold and marketed in Australia. With the registration now in place, Cincinnatiense and its local distribution partner, Regional Health Care Group (RHCG), are initiating preparations for sales, training, and education activities in the market. RHCG was appointed as Cincinnatiense's distributor for Australia in anticipation of the Clamp, and has been awaiting approval before starting commercial activities. With the Cincinnatiense Clamp now registered by the TGA, the companies can begin coordinated preparations to introduce the system to dialysis clinics across the country. Announcement • Oct 21
Redsense Medical AB (publ) to Report Q3, 2025 Results on Nov 19, 2025 Redsense Medical AB (publ) announced that they will report Q3, 2025 results on Nov 19, 2025 Announcement • Aug 21
Redsense Medical AB (Publ) Announces Executive Changes Redsense Medical AB (publ) announced that on May 28, AGM was held and Mike Griffiths and Johannes Köpple was elected as new Directors for the period until the end of the next AGM, replacing Peter Larsson. Announcement • Jul 22
Redsense Medical AB (publ) to Report Q2, 2025 Results on Aug 20, 2025 Redsense Medical AB (publ) announced that they will report Q2, 2025 results on Aug 20, 2025 Announcement • May 07
Redsense Medical AB (publ)'s Clamp Nears Market Launch as Summative Evaluation Review Completed Redsense Medical AB (publ) announced that the summative evaluation review for the Clamp has been successfully completed by the independent test house. This marks a key milestone in the product's journey to market, confirming its compliance with the highest standards of performance, safety, and reliability. With the evaluation phase now concluded, the Clamp is in its final pre-launch stage. Remaining steps now include the finalization and release of internal design documentation, instructions for use, labelling, and completing the certificate of conformity, including CE marking. The Clamp will be launched initially through active distributors in both the UK and Canada, with first sales expected by the end of this month. Announcement • Apr 24
Redsense Medical AB (publ) Appoints Peter Larsson as New Member of the Board of Directors Redsense Medical AB (publ) announced that at the Extra General Meeting on April 24, 2025, approved the appointment of Peter Larsson as New Member of the Board of Directors, for the period until the end of the next Annual General Meeting. It was noted that the Board of Directors thus now consist of Susanne Olauson, Martin Roos and Peter Larsson. Announcement • Apr 15
Redsense Medical AB (publ) to Report Q1, 2025 Results on May 14, 2025 Redsense Medical AB (publ) announced that they will report Q1, 2025 results on May 14, 2025 Announcement • Feb 10
Redsense Medical AB (publ) Announces CFO Changes Redsense Medical AB (publ) announced that Peter Larsson is taking over as CFO, as Jennie Kardell decided to leave the company to pursue other opportunities. Peter Larsson will be joining the team as part-time CFO consultant. Peter Larsson, born in 1969, has held multiple leading positions as CFO and CEO for a variety of companies across industries and geographies, including listed companies across markets. He has over 30 years of experience as CFO and a proven track record in scaling healthcare and technology companies. The company will also have additional support from a Postdoc intern from Karolinska Institute and a master student from Halmstad University, who will both assist the company on a part-time basis. Redsense participated in Karolinska Institute's Internship Program HT24, and hired a part-time Postdoc who is assisting the company during 6 months in health economics research, communication, and regulatory affairs. The program is co-financed by Karolinska Institute career services and Redsense. The part-time master student from Halmstad University will also assist with commercial operations such as supply chain management, quality management, and sustainability issues. Announcement • Jan 31
Redsense Medical AB (publ) Announces Demise of Malin Almgren, Board Member Redsense Medical AB (publ) announced that board member, Malin Almgren has passed away. Malin Almgren has been a dedicated member of the board since May 2023 and has with her strong research focus provided valuable insights to the company. Redsense Medical's nomination committee will present a proposal for new board members ahead of the upcoming annual general meeting. Announcement • Jan 28
Redsense Medical AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025 Redsense Medical AB (publ) announced that they will report fiscal year 2024 results on Feb 26, 2025 Announcement • Jan 21
Redsense Medical Announces Completion of Clamp Usability Testing Redsense Medical announced the completion of the usability testing phase with the Redsense Clamp, entering the final stage towards CE marking. A study was conducted with Canadian home dialysis patients that used the Redsense blood leakage alarm together with the Cincinnati Clamp, under supervision of Dr. Christopher Chan, Director of Division of Nephrology and Medical Director at the University Health Network in Toronto, Canada. The results of the study will be published in a scientific article. The next step is to finalize a usability report, to be reviewed by a Quality Assurance Provider, in order to CE-Mark the Cincinnati Clamp. The Clamp was also tested by German Intensive Care nurses, and that data has now also been received. All usability data is being analysed and compiled into a report, while in the meantime the last work to finalize and translate instructions for use, educational material, marketing material, and labelling have also begun. Announcement • Oct 28
Redsense Medical AB (publ) to Report Q3, 2024 Results on Nov 26, 2024 Redsense Medical AB (publ) announced that they will report Q3, 2024 results on Nov 26, 2024 New Risk • Sep 16
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.97m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 1.2% per year over the past 5 years. Market cap is less than US$10m (€8.97m market cap, or US$9.98m). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (kr24m revenue, or US$2.4m). Announcement • Sep 16
Redsense Medical AB (publ) Announces Board Changes Redsense Medical AB (publ) announced that board chairman Eva Walde has chosen to leave her post due to personal reasons. The board has unanimously decided to appoint board member Susanne Olauson as acting board chairman until the next ordinary general meeting, when a permanent successor will be elected. Reported Earnings • Aug 30
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr10.5m (up 106% from 2Q 2023). Net income: kr625.0k (up kr3.59m from 2Q 2023). Profit margin: 5.9% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Announcement • Jul 31
Redsense Medical AB (publ) to Report Q2, 2024 Results on Aug 29, 2024 Redsense Medical AB (publ) announced that they will report Q2, 2024 results on Aug 29, 2024 New Risk • Jul 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.7m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (kr20m revenue, or US$1.9m). Market cap is less than US$100m (€11.0m market cap, or US$12.0m). Announcement • May 29
Redsense Medical AB Announces CEO Changes The Board of Directors of Redsense Medical AB and Pontus Nobréus, CEO since August 2022, have reached a mutual agreement that Pontus Nobréus will leave his position as CEO. The board of Redsense has appointed the current CFO, Jennie Kardell, as acting CEO. Work on recruiting a new CEO will begin immediately. Reported Earnings • May 09
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr2.69m (down 62% from 1Q 2023). Net loss: kr2.64m (down kr3.05m from profit in 1Q 2023). Reported Earnings • Apr 22
Full year 2023 earnings released: kr0.32 loss per share (vs kr0.62 loss in FY 2022) Full year 2023 results: kr0.32 loss per share (improved from kr0.62 loss in FY 2022). Revenue: kr25.5m (up 52% from FY 2022). Net loss: kr4.51m (loss narrowed 49% from FY 2022). Announcement • Apr 09
Redsense Medical AB (publ) to Report Q1, 2024 Results on May 08, 2024 Redsense Medical AB (publ) announced that they will report Q1, 2024 results on May 08, 2024 Reported Earnings • Feb 28
Full year 2023 earnings released: kr0.32 loss per share (vs kr0.62 loss in FY 2022) Full year 2023 results: kr0.32 loss per share (improved from kr0.62 loss in FY 2022). Revenue: kr25.6m (up 53% from FY 2022). Net loss: kr4.51m (loss narrowed 49% from FY 2022). Announcement • Jan 29
Redsense Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024 Redsense Medical AB (publ) announced that they will report fiscal year 2023 results on Feb 27, 2024 Board Change • Jan 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Annette Colin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 09
Redsense Medical Appoints Eva Walde as Chairman of Board of Directors Eva Walde has been appointed Chairman of Redsense Medical's Board of Directors until a new Chairman is elected by the Annual General Meeting. The appointment follows the deeply saddening passing of Redsense Medical's former Chairman of the Board, Patrik Byhmer. Eva Walde has been a valued member of Redsense Medical's Board of Directors since 2023 and has over 30 years of experience in senior positions in pharmaceuticals, medical devices, diagnostics and biotechnology industries, mainly in marketing and sales. Eva currently serves on the Board of Directors of Sedana Medical AB, Senzime AB, Scale Up Life Science AB, Epigenica AB and FrostPharma AB. Reported Earnings • Nov 10
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr5.56m (up 333% from 3Q 2022). Net loss: kr1.01m (loss narrowed 57% from 3Q 2022). Announcement • Oct 28
Redsense Medical AB Announces Nomination Committee Appointed for the 2024 Annual General Meeting Nomination Committee has been established for the 2024 Annual General Meeting of Redsense Medical AB. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on May 9, 2023, consists of: Patrik Byhmer, appointed by Seventh Sense Adventures Holding AB; Johannes Köpple, appointed by ShapeQ GmbH; Oscar Bergman, appointed by Swedbank Robur Fonder. Patrik Byhmer, Chairman of the Board, is the convener of the Nomination Committee. The Nomination Committee's task is to submit proposals to the Annual General Meeting regarding; Election of Chairman of the Meeting, number of Board members, election of Chairman of the Board and other members of the Board, fees to the Board of Directors and, where applicable, remuneration for committee work divided between each Board member, proposal for election of auditor and auditor's fees and, to the extent deemed necessary, proposal for amendments to the current instruction for the Nomination Committee. Announcement • Oct 11
Redsense Medical AB (publ) to Report Q3, 2023 Results on Nov 09, 2023 Redsense Medical AB (publ) announced that they will report Q3, 2023 results on Nov 09, 2023 Board Change • Sep 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Annette Colin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr5.15m (up 108% from 2Q 2022). Net loss: kr2.97m (loss widened 39% from 2Q 2022). Announcement • Jul 31
Redsense Medical AB (publ) to Report Q2, 2023 Results on Aug 29, 2023 Redsense Medical AB (publ) announced that they will report Q2, 2023 results on Aug 29, 2023 Board Change • Jul 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Annette Colin was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
